Jaguar Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. on November 24, 2017. The filing reports the entry into a material definitive agreement involving a registered direct offering of common stock.
Key Financial Metrics and Transaction Details
- Transaction Type: Registered Direct Offering of 2,000,000 shares of voting common stock.
- Purchase Price: $0.25 per share.
- Investor: L2 Capital, LLC.
- Gross Proceeds: $0.50 million (2,000,000 shares x $0.25).
- Transaction Expenses: Approximately $9,000.
- Net Proceeds: Approximately $0.49 million.
- Use of Proceeds: Commercialization of Mytesi (lead prescription drug product) and working capital/general corporate purposes.
- Concurrent Agreement: A Common Stock Purchase Agreement (CSPA) was also entered into for an Equity Line Offering of up to 12,100,000 shares, with 10,000,000 shares offered via an equity line of credit.
Note: This filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics for the company's operations.
Material Changes
The filing details a material change in the company's capital structure through the issuance of new equity. No comparative financial data or changes versus prior periods are provided in this specific document.
Outlook, Risks, and Management Commentary
Management intends to utilize the net proceeds to advance the commercialization of Mytesi. The filing includes a standard disclaimer regarding forward-looking statements, noting that predictions regarding the use of proceeds are subject to risks, uncertainties, and assumptions beyond the company's control. The company does not plan to update these statements unless required by law.
Key Facts for Investor Verification
- Verify the closing of the Registered Direct Offering and the receipt of approximately $0.49 million in net proceeds.
- Review the separate Form 8-K filed concurrently for details on the Equity Line Offering (up to 12,100,000 shares).
- Confirm the specific terms of the Share Purchase Agreement filed as Exhibit 10.1.
- Monitor the progress of Mytesi commercialization as the primary use of funds.